Scarica l'app Stockscreener
1.5899
3.05%
-0.0501
Precedente Chiudi:
$1.64
Aprire:
$1.63
Volume 24 ore:
826.20K
Relative Volume:
0.30
Capitalizzazione di mercato:
$113.23M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-2.1199
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
+0.63%
1M Prestazione:
+21.84%
6M Prestazione:
+467.45%
1 anno Prestazione:
+54.37%
Intervallo 1D:
$1.5524
$1.64
Intervallo di 1 settimana:
$1.54
$1.71
Portata 52W:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.59 | 116.79M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.56 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
845.21 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.74 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.47 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn
Janus Henderson Group PLC Acquires Significant Stake in Ovid Therapeutics Inc - GuruFocus
Roth Capital Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals - Investing.com
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals By Investing.com - Investing.com South Africa
Ovid Therapeutics Stockholders Approve Key Proposals - TipRanks
Roth Capital Initiates Coverage of Ovid Therapeutics (OVID) with Buy Recommendation - Nasdaq
Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug - Investing.com Canada
OVID: Roth Capital Initiates Coverage with a "Buy" Rating at $3. - GuruFocus
What analysts say about Ovid Therapeutics Inc stockTrading Volume Surges & Capitalize On Fast Trends - earlytimes.in
Will Ovid Therapeutics Inc. stock deliver long term returns - Newser
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser
Will Ovid Therapeutics Inc. (1OT) stock gain from lower interest ratesPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Will Ovid Therapeutics Inc. stock gain from strong economyDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Ovid Therapeutics Inc. (1OT) stock benefit from sector leadershipJuly 2025 Opening Moves & Verified Chart Pattern Signals - Newser
Is Ovid Therapeutics Inc. (1OT) stock attractive for growth fundsJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer - marketscreener.com
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer - Investing.com
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - Enidnews.com
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsProduct Launch & Real-Time Chart Pattern Alerts - Newser
Is Ovid Therapeutics Inc. (1OT) stock dividend growth reliableMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
IPO Launch: Is Ovid Therapeutics Inc stock positioned well for digital economyWeekly Gains Summary & Weekly Stock Performance Updates - moha.gov.vn
November 2025's Top Penny Stock Opportunities - simplywall.st
What analysts say about Ovid Therapeutics Inc 1OT stockVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
HC Wainwright & Co. Maintains Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Equities Analysts Issue Forecasts for OVID Q4 Earnings - MarketBeat
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):